UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): May 16, 2005



                           DRAGON PHARMACEUTICAL INC.
                           -------------------------
             (Exact name of registrant as specified in its charter)


              Florida                     0-27937                65-0142474
              -------                     -------                ----------
(State or Other Jurisdiction of    (Commission File Number)    (IRS Employer
        Incorporation)                                       Identification No.)

            1055 Hastings Street, Suite 1900
              Vancouver, British Columbia                  V6E 2E9
              ----------------------------                 -------
        (Address of Principal Executive Offices)          (Zip Code)


                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition

     Dragon  Pharmaceutical  Inc.  announced its financial results for the first
quarter of 2005 on the attached press release.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

          Exhibit No.    Exhibit Description
          ----------     -------------------

              99         Press  release  announcing  financial  results  for the
                         first quarter of 2005.




                                       2

<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                          DRAGON PHARMACEUTICAL INC.,
                                          a Florida Corporation


Dated:  May 18, 2005                      /s/ Maggie Deng
                                          --------------------------------------
                                          Maggie Deng
                                          Chief Operating Officer



                                       3
<PAGE>


                                  EXHIBIT INDEX


         Exhibit No.     Description
         ----------      -----------

            99           Press  release  dated  May  16,  2005  titled   "Dragon
                         Pharmaceutical  Announces  Financial  Results  for  the
                         First  Quarter of 2005 with 65%  Increase  in  Revenues
                         from the prior year"





                                       4
[{"type": "8-K", "sequence": "1", "filename": "form8k.txt", "description": "FOR EVENT MAY 16, 2005", "secsgml_size_bytes": 3692}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "05844830"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): May 16, 2005

                           DRAGON PHARMACEUTICAL INC.
                           -------------------------
             (Exact name of registrant as specified in its charter)

              Florida                     0-27937                65-0142474
              -------                     -------                ----------
(State or Other Jurisdiction of    (Commission File Number)    (IRS Employer
        Incorporation)                                       Identification No.)

            1055 Hastings Street, Suite 1900
              Vancouver, British Columbia                  V6E 2E9
              ----------------------------                 -------
        (Address of Principal Executive Offices)          (Zip Code)

                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition

     Dragon  Pharmaceutical  Inc.  announced its financial results for the first
quarter of 2005 on the attached press release.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

          Exhibit No.    Exhibit Description
          ----------     -------------------

              99         Press  release  announcing  financial  results  for the
                         first quarter of 2005.

                                       2
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                          DRAGON PHARMACEUTICAL INC.,
                                          a Florida Corporation

Dated:  May 18, 2005                      /s/ Maggie Deng
                                          --------------------------------------
                                          Maggie Deng
                                          Chief Operating Officer

                                       3
EXHIBIT INDEX

         Exhibit No.     Description
         ----------      -----------

            99           Press  release  dated  May  16,  2005  titled   "Dragon
                         Pharmaceutical  Announces  Financial  Results  for  the
                         First  Quarter of 2005 with 65%  Increase  in  Revenues
                         from the prior year"

                                       4